Immune disorder correction in maxillofacial odontogenic osteomyelitis

Abstract

Among purulent-inflammatory diseases of the jaws, odontogenic osteomyelitis of the maxillofacial region is the most common. Its clinical course is largely determined by the species composition and virulence of the microflora present in the oral cavity and scalp, as well as the nature and severity of systemic and local immunometabolic disorders. Interest in this pathology is also due to the high risk of an unfavorable outcome due to the anatomical features of the region being examined. Furthermore, more than 5% of cases result in chronic inflammation. Immune and oxidative processes are integral components of most pathogenic mechanisms of disease development. Treatment of odontogenic osteomyelitis of the maxillofacial region, despite the availability and adequate equipment of modern clinics in Russia, remains a challenging task, as evidenced by the high rate of chronicity of this disease. The objective of this study was to establish the clinical and immunological efficacy of immunomodulators and membrane protectors in patients with odontogenic osteomyelitis of the maxillofacial region. This study established for the first time the nature and extent of immunometabolic disturbances at the systemic and local levels in patients with odontogenic osteomyelitis of the maxillofacial region. The insufficient effectiveness of standard treatment in correcting immune and oxidative status disorders was determined. It was also demonstrated for the first time that the clinical and laboratory effects of pharmacotherapy regimens are arranged in descending order: Longidaza + Phosphogliv Forte → Polyoxidonium + Phosphogliv Forte → Gepon + Phosphogliv Forte.